SCHEMBL23973004

SCHEMBL23973004

CC(C)(C)c1cccc(-c2cccc(CC(=O)N3CCCc4nc(C5(c6cccc(Cl)c6)CC5)[nH]c(=O)c4C3)c2)c1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
FFAR2 O15552 2/20 0.34
CLPP Q16740 1/20 0.34
PDE4B Q07343 4/20 0.33
MTHFD2 P13995 2/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
OPRD1 P41143 2/20 0.33
OPRK1 P41145 2/20 0.33
OPRM1 P35372 1/20 0.33
EPHX1 P07099 1/20 0.32
EPHX2 P34913 1/20 0.32
SCN5A Q14524 1/20 0.32
KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30284029 1.00 MEN1 (0.34) MEN1KMT2ALMNATSHRTRPV1
SCHEMBL30284392 0.96 MTHFD2 (0.37) TRPV1FFAR2CLPPMTHFD2MAPT
SCHEMBL23973002 0.96 MTHFD2 (0.37) TRPV1FFAR2CLPPMTHFD2MAPT
SCHEMBL34464288 0.96 MEN1 (0.36) MEN1KMT2ALMNATSHRCLPP
SCHEMBL26670593 0.96 MEN1 (0.36) MEN1KMT2ALMNATSHRCLPP
SCHEMBL30284073 0.95 TRPV1 (0.35) MEN1KMT2ALMNATSHRTRPV1
SCHEMBL23973063 0.95 TRPV1 (0.35) MEN1KMT2ALMNATSHRTRPV1
SCHEMBL23973502 0.93 MEN1 (0.42) MEN1KMT2ALMNATSHRTRPV1
SCHEMBL30284423 0.93 MEN1 (0.42) MEN1KMT2ALMNATSHRTRPV1
SCHEMBL23973000 0.93 TRPV1 (0.39) MEN1KMT2ATRPV1FFAR2MTHFD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115427409-A Pyrimidin-4 (3H) -one derivatives as TRPV4 antagonists 拉夸里亚创药株式会社 2022-12-02 CN claimed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
CN-115776890-A TRPV4 inhibitors as therapeutic agents for eye diseases 拉夸里亚创药株式会社 2023-03-10 CN disclosed
CN-115427409-A Pyrimidin-4 (3H) -one derivatives as TRPV4 antagonists 拉夸里亚创药株式会社 2022-12-02 CN disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 MEN1 3786/4885KMT2A 4196/4885LMNA 4199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.